Product Description
The global CVC market was valued at $1 billion in 2025. This is expected to increase over the forecast period at a CAGR of 1.4% to reach $1.1 billion by 2032.
The full report suite on the global market for central venous catheters (CVCs) includes acute CVCs and chronic CVCs. The acute CVC category encompasses both power-injectable and non-power-injectable devices. The chronic CVC category encompasses both power-injectable and non-power-injectable devices, too.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Global Central Venous Catheter Market Trends

Power-injectable CVCs have become a dominant feature of the market and continue to shape value dynamics. These devices are increasingly preferred for patients with difficult venous access and for care settings requiring compatibility with contrast-enhanced imaging. As power-injectable CVCs become more widely adopted and represent a larger share of total placements, their higher price point supports ASP stability and contributes to overall market value growth, even in the absence of strong unit expansion.
Global Central Venous Catheter Market Share Insights

- Teleflex, in 2025, held the leading position in the CVC market, dominating both the acute and chronic segments. This leadership was established following its acquisition of Arrow International in 2007, which provided a comprehensive range of catheter products. Teleflex entered the chronic CVC market in 2013 with the ARROW® JACC featuring Chlorag+ard® Technology, offering antimicrobial and antithrombogenic properties suitable for both short-term and long-term use. The company primarily represented the triple-lumen subcategory of CVCs and reported robust growth, driven partly by increased CVC sales.
- Becton Dickinson (BD) ranked as the second-leading competitor in the 2025 CVC market, largely due to its presence in the chronic CVC segment. BD’s brands, such as PowerHohn®, Hohn®, PowerLine®, PowerHickman® and Hickman® Trifusion® catheters, have become synonymous with chronic CVCs. Despite a declining growth rate in the chronic CVC market, BD’s established market position and brand recognition have contributed to its significant market share.
- Braun secured the third-leading position in the total CVC market in 2025 by focusing primarily on the acute CVC market. Leveraging its strong presence in neighboring markets such as Scandinavia and Switzerland, B. Braun maintained a significant share through its Certofix® and Cavafix® CVC product lines. Notably, B. Braun’s Certofix® Protect line of CVCs, marketed as antimicrobial devices, allowed it to compete effectively in the growing antimicrobial market segment.
Global Central Venous Catheter Market Segmentation Summary
- Acute Catheter Market– Further Segmented Into:
- Device Type: Power-Injectable and Non-Power-Injectable
- Chronic Catheter Market– Further Segmented Into:
- Device Type: Power-Injectable and Non-Power-Injectable
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Region | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.